# Milestone Scientific Inc.: Form 10-Q for the period ended Mar 31, 2009

- Company: [Milestone Scientific Inc.](/companies/mlss.md) (CIK 855683)
- Form: 10-Q
- Filed: 2009-05-07
- Accepted by EDGAR: May 7, 2009, 15:48 ET
- Period: 2009-03-31
- Accession: 0001362310-09-006759
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/855683/000136231009006759/c84663e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/855683/000136231009006759/

## Management's discussion and analysis

As filed, 23,209 characters.

The following discussions of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-Q. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements. See “Risk Factors” on Part II. ITEM 1A of this Form 10-Q.

### OVERVIEW

During the first quarter of 2009, Milestone remained focused on advancing efforts to achieve its two primary objectives; those being:

- Optimizing our tactical approach to product sales and marketing in order to materially increase penetration of the global dental and medical markets with our proprietary, patented Computer-Controlled Local Anesthesia Deliver (C-CLAD) solution, the *STA Single Tooth Anesthesia System (STA System*); and
- Identifying and pursing strategic collaborations with third parties to jointly develop new products utilizing our patented CompuFlo pressure force technology for novel new medical applications.

### STA System Awards — Industry Recognition

Since its market introduction in the spring of 2007, the *STA System* has received rave reviews and awards from the dental industry. In July 2007, noted industry publication *Dentistry Today* featured the *STA System* as one of the “Top 100 Products in 2007,” helping to promote much broader recognition of the instrument and validating the *STA System’*s value proposition for dentists and patients, alike. In April 2008, *Medical Device & Diagnostic Industry* magazine distinguished the *STA System* as a 2008 Medical Design Excellence Award winner in the “Dental Instruments, Equipment and Supplies” product category. Of the 33 products to receive this coveted award, the *STA System* was one of only two winning products that serve dental practitioners.

In December 2008, the *STA System* was again recognized as one of the dental industry’s best technological innovations, winning a “Townie Choice Award” from *Dentaltown Magazine* in the category “Anesthetics: Technique System”. This marked the second consecutive year that Milestone won a “Townie Choice Award” — in 2007, the Company won the same award for its *CompuDent/The Wand.* Also in December 2008, Milestone’s STA System was named as a *Dental Products Report “*Top 100 2008 Product of Distinction. Each year, *DPR* spotlights the year’s Top 100 products. Of these 100 products, 50 are the ones most often inquired about by *DPR’*s readers via an online and Product Information Card reader service program. The other 50 represent “New Classics,” which recognize both old and newer products and categories chosen by *DPR’s* editorial staff for their “perceived impact on driving innovation or helping to establish a new, higher standard of care for patients.” The *STA System* was recognized as a “New Classic” in the Technology category.

### Second Annual Symposium on C-CLAD

In addition to winning noted acclaim among leading dental publications, our award winning *STA System* has also been gaining the support of many of the world’s leading dental practitioners and key opinion leaders. In February 2008, we hosted the First International C-CLAD Symposium in New Orleans, welcoming a distinguished panel of dental experts who gathered to discuss advancements in the scientific and clinical practice communities toward the common goal of advancing the science, knowledge and art of C-CLAD in dentistry. The forum yielded a number of exciting ideas on how Milestone can integrate the *STA System* not only into dental school curricula, but also extend messaging regarding its many unique benefits to the dental community and patients, alike.

On May 1-3, 2009, Milestone will be hosting the 2nd Annual Symposium on C-CLAD in Amelia Island, Florida. Stanley Malamed, DDS, Professor of Anesthesia & Medicine at the University of Southern California, School of Dentistry, will again serve as Chairman of the invitational event. With attendance expected to be triple that of 2008, this year’s Symposium will cover a broad range of C-CLAD-related topics including:

- The History of C-CLAD
- Treating with Connection
- Heart Rate Study
- *STA* Compassionate Care in the 21st Century
- Injection Advances and Challenges
- Physiologic and Clinical Characteristics of PDL Anesthesia Delivered by a High Pressure Syringe and a Computerized Device
- The *STA* for Tots and Teens
- Computerized Local Anesthesia in Dentistry: A Review
- Today’s Technology
- Managing a Successful Dental Practice: Why People Keep Coming Back
- *STA* - The Dental School’s Perspective
- Futuristic Vistas: The Dentist/Hygienist Partnership

### STA System Growth

Since its market introduction in early 2007, the STA System has been used to deliver tens of millions of safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the *STA System* is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide. The utility and value of the *STA System* is perhaps best summarized by Dr. Joe Blaes, who wrote in the December 2008 edition of *Dental Economics, “*I tried the *STA System* and my patients absolutely love it. This is a no brainer — go get one ASAP!”

### Global Distribution Network

The *STA System* and related handpieces are marketed to the dental industry in the United States and Canada by many of the nation’s leading dental supply companies including Henry Schein, Inc., Patterson Dental Supply, Benco Dental, Burhart Dental, Goetze Dental, and Atlanta Dental. Collectively, our network has more than 2,450 independent sales representatives trained to sell the *STA System* and related handpieces to dentists throughout the United States and Canada.

On the global front, we also have granted exclusive marketing and distribution rights for the *STA System* to select dental suppliers in various international regions. They include Istrodent in South Africa and Unident in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.

Subsequent to the quarter ending March 31, 2009, the Company signed an Exclusive Distribution and Marketing Agreement with China National Medicines Corporation d/b/a Sinopharm. Sinopharm is China’s largest domestic manufacturer, distributor and marketer of pharmaceuticals and importer of medical devices and the country’s largest domestic distributor of dental anesthetic carpules to the Chinese dental industry.

As a result of growing market awareness and appreciation of the STA System, coupled with our active marketing efforts, sales of the instrument (and related handpieces) yielded four consecutive quarters of growth in 2008. In the first quarter of this year, we saw no indication that this trend is slowing or reversing. Conversely, sales of the *STA System* and handpieces helped increase total revenues 59% during the three months ended March 31, 2009, when compared to the same three month period in the prior year. As we progress through 2009, we plan to expand Milestone’s worldwide sales and marketing resources to accelerate our revenue growth. Particular emphasis will be placed on strengthening distribution channels in Europe.

### Segmented Sales Performance

The following table shows a breakdown of our product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

| DOMESTIC | Three Months Ended March 31, 2009 |  | 2008 |  |
| --- | ---: | ---: | ---: | ---: |
| Instruments | $526,413 | 35.6% | $81,144 | 9.0% |
| Handpieces | 931,810 | 63.0% | 799,744 | 89.1% |
| Other | 20,272 | 1.4% | 16,827 | 1.9% |
| Total Domestic | $1,478,495 | 100.0% | $897,715 | 100.0% |
| **INTERNATIONAL** |  |  |  |  |
| Instruments | $265,539 | 36.6% | $138,061 | 28.2% |
| Handpieces | 463,402 | 63.8% | 351,482 | 71.7% |
| Other | (2,617) | -0.4% | 732 | 0.1% |
| Total International | $726,324 | 100.0% | $490,275 | 100.0% |
| **DOMESTIC/INTERNATIONAL ANALYSIS** |  |  |  |  |
| Domestic | $1,478,495 | 67.1% | $897,715 | 64.7% |
| International | 726,324 | 32.9% | 490,275 | 35.3% |
| Total Product Sales | $2,204,819 | 100.0% | $1,387,990 | 100.0% |

The Company earned gross profits of 58% and 67% in for the three months ended March 31, 2009 and 2008, respectively. However, our revenues and related gross profits have not been sufficient to support our overhead, new product introduction and research and development expenses. Although the Company anticipates expending funds for research and development in 2009, these amounts will vary based on the operating results for each quarter. The Company has incurred operating losses and negative cash flows from operating activities since its inception. The Company is actively pursuing the generation of positive cash flows from operating activities through increase in revenue, assessment of current contracts and current negotiations and reduction in operating expenses. The Company, at March 31, 2009, expects to have sufficient cash reserves to meet all of its anticipated obligations through December 31, 2009.

### New Product Development and Commercialization

In keeping with the Company’s stated goal for leveraging our patented CompuFlo technology in new medical applications, Milestone’s management team has also continued to identify and pursue opportunities to form strategic collaborations in the areas of self-administered drug delivery, injections for osteoarthritis pain management and epidurals. The response to Milestone’s proprietary technology with whom Milestone has engaged in meaningful teaming discussions has continued to be encouraging. Throughout 2008, the Company met with healthcare companies who expressed interest in potential applications of the CompuFlo technology. As Milestone progresses through 2009, the Company will maintain its pursuit of CompuFlo-based product development prospects that are deemed the most promising and commercially viable, and offer the greatest potential for allowing Milestone to fully realize the product development and commercialization opportunities.

### Executive Management Change

On March 27, 2009, we accepted the resignation of our Chief Executive Officer, who chose to leave Milestone to pursue a new career opportunity. Our Chairman of the Board has temporarily assumed the post of interim Chief Executive Officer and will remain as such until a suitable replacement has been identified and appointed by our Board of Directors.

### Technology Rights

The technology underlying our *SafetyWand* and *CompuFlo* technology and an improvement to the controls for *CompuDent* were developed by our Director of Clinical Affairs and assigned to us. We purchased this technology pursuant to an agreement dated January 1, 2005, for 43,424 shares of restricted common stock and $145,000 in cash, paid on April 1, 2005. In addition, our Director of Clinical Affairs will receive additional deferred contingent payments of 2.5% of our total sales of *CompuDent* and Wand Plus units using some of these technologies, and 5% of our total sales of *STA* units and handpieces using some of our other technologies. If products produced by third parties use any of these technologies, under a license from Milestone, then he will also receive the corresponding percentage of the consideration received by us for such sale or license.

### Summary of Significant Accounting Policies, Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, inventories, stock-based compensation, and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

#### Accounts Receivable

The realization of Accounts Receivable will have a significant impact on the Company. Consequently, Milestone estimates losses resulting from the inability of its customers to make payments for amounts billed. The collectability of outstanding amounts is continually assessed.

#### Inventories

Inventory costing, obsolescence and physical control are significantly important to the on-going operation of the business. Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.

#### Impairment of Long-Lived Assets

The long lived assets of the Company, principally patents and trademarks are the base features of the business. We review long-lived assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The carrying value of the asset is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets.

#### Revenue Recognition

Revenue from product sales is recognized net of discounts and allowances to our domestic distributors on the date of arrival of the goods at the customer’s location as shipments are FOB destination. Shipments to our international distributor are FOB our warehouse and revenue is therefore recognized on shipment. In both cases the price to the buyer is fixed and the collectability is reasonably assured. Further, we have no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Customer acceptance is considered made at delivery. Our only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.

### Results of Operations

The consolidated results of operations for the three months ended March 31, 2009 compared to the same three month period in 2008 reflect our focus and development on the *STA System* , as well as continuing efforts on identifying collaborative partners for new product development utilizing our *CompuFlo* technology.

The following table sets forth for the periods presented statement of operations data as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results.

|  | Three Months Ended March 31 2009 |  | 2008 |  |
| --- | ---: | ---: | ---: | ---: |
| Products sales, net | $2,204,819 | 100% | $1,387,990 | 99% |
| Royalty income | — | 0% | 14,163 | 1% |
| Total revenue | 2,204,819 | 100% | 1,402,153 | 100% |
| Cost of products sold | 916,550 | 42% | 463,924 | 33% |
| Gross Profit | 1,288,269 | 58% | 938,229 | 67% |
| Selling, general and administrative expenses | 1,728,815 | 78% | 1,471,978 | 105% |
| Research and development expenses | 67,622 | 3% | 48,319 | 3% |
| Total operating expenses | 1,796,437 | 81% | 1,520,297 | 108% |
| Loss from operations | (508,168) | -23% | (582,068) | -42% |
| Other income — interest & expense | (53,474) | -2% | (33,817) | -2% |
| Net loss | $(561,642) | -25% | (615,885) | -44% |

### Three months ended March 31, 2009 compared to three months ended March 31, 2008

Total revenues for the three months ended March 31, 2009 and 2008 were $2,204,819 and $1,402,153, respectively. The total increase in product sales of $816,829 or 58.8%, in 2009 over 2008 is primarily the result of the continued *STA* product growth. Domestic *STA* unit sales increased $472,094 in 2009 over 2008. This dramatic increase is due to a lack of sales by our exclusive distributor in the first quarter of 2008. The exclusive distributor arrangement was terminated in the second quarter of 2008 and a non exclusive arrangement was implemented with several distributors in the second quarter of 2008. In the domestic market, handpiece sales were higher, increasing by $132,066 or 16.5%. On the international front, unit sales increased in the first quarter of 2009 over 2008 by $127,478 or 92.3% principally due to increased market penetration for the *STA System*. Internationally, handpieces also increased rising $111,920, 24.2% due to an increase in both *STA* and *CompuDent* handpieces.

Cost of products sold for the three months ended March 31, 2009 and 2008 were $916,550 and $463,924, respectively. The $452,626 or 97.6% increase is primarily attributable to an increase in sales volume.

For the three months ended March 31, 2009, Milestone generated a gross profit of $1,288,269 or 58% as compared to a gross profit of $938,229 or 67% for the three months ended March 31, 2008. The decrease in gross profit percentage is due to the decrease in the selling price of STA in the second quarter of 2008. The total increase in gross profit dollars of $350,040 is due to an increase in sales volume.

Selling, general and administrative expenses for the three months ended March 31, 2009 and 2008 were $1,728,815 and $1,471,978, respectively. The $256,837, or 17.4%, net increase is described in the following sections of this report. Although the Company continues to reduce expenses, the 2009 first quarter increase was due to higher expenses relating to promoting continued sales growth. Marketing expenses increased by $286,439, principally due to increased media placement (approximately $76,000), attendance at trade shows and various sales promotions. Sales expenses increased by $63,853 as the Company increased field sales personnel and increased participation and presence at trade shows. Additionally, third party sales representative commissions increased by $21,023, based on increased domestic sales of the *STA Systems* and related handpieces. Other variable sales expenses for the *STA System* and handpieces increased in the first quarter of 2009 due to higher royalty payments ($34,968) and increased international selling participation costs of approximately $21,000. On the positive side of the ledger, professional accounting services decreased by $92,419 in the first quarter of 2009 over the same period in 2008, due to completion of the Sarbanes Oxley initiative and lower audit fees. There was a decrease in consulting services of $57,056.

Research and development expenses for the three months ended March 31, 2009 and 2008 were $67,622 and $48,319, respectively. The increase of $19,303 was attributable to a research project and product life testing incurred the first quarter of 2009.

The loss from operations for the three months ended March 31, 2009 and 2008 was $508,168 and $582,068, respectively. The $73,900 or 12.7% decrease in loss from operations is explained above.

Interest income of $1,804 was earned for the three months ended March 31, 2009 compared with $3,236 for the same period in 2008. Interest income declined due to lower cash balances and lower interest rates.

Interest expense was $47,403 and amortization of debt issuance was $7,875 relating to the line of credit and long term note payable for the first quarter of 2009 compared to interest expense of $30,924 and amortization of debt issuance expense of $6,129 for the same quarter in 2008.

For the reasons explained above, net loss for the three months ended March 31, 2009 was $561,642 as compared to a net loss of $615,885 for the three months ended March 31, 2008. The $54,243 or 8.8% decrease in net loss is primarily a result of the increase in sales and gross margin dollars, partially offset by one time increases in market consulting costs and a decrease in other selling, general and administrative expenses.

### Liquidity and Capital Resources

As of March 31, 2009, we had cash and cash equivalents of $500,668 and working capital of $1,190,957. Milestone incurred net losses of $561,642 and $615,885 and negative cash flows from operating activities of $200,257 and $407,598 for the three months ended March 31, 2009 and 2008, respectively.

For the three months ended March 31, 2009, our net cash used in operating activities was $200,257. This was attributable primarily to a net loss of $561,642 adjusted for noncash items of $262,651 and changes in operating assets and liabilities of $98,734, principally common stock and options issued for compensation, consulting and vendor services.

For the three months ended March 31, 2009, Milestone used $42,740 in investing activities. This was primarily attributable to $12,609 of legal fees related to new patent application. Capital expenditures of $30,131 were primarily for the purchase of STA trade show booths.

As of March 31, 2009, Milestone had recorded on the Balance Sheet a $1.3 million line of credit from a stockholder, originally issued in June 2007. Additionally, the Company has recorded a long term note payable of $450,000 from the same stockholder. Both of these loans were outstanding at March 31, 2009.

The Company has incurred operating losses and negative cash flows from operating activities since its inception. The Company is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses. The Company, at March 31, 2009, expects to have sufficient cash reserves to meet all of its anticipated obligations through December 31, 2009. If the Company is unable to generate positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that the Company will be able to achieve positive operating cash flows or that traditional capital can be raised on terms and conditions satisfactory to the Company. If additional capital is required and cannot be raised, then the Company would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect the Company’s operating results.

The Company’s recurring losses and negative operating cash flows raises substantial doubt about its ability to continue as a going concern. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty.

## Market risk

As filed, 149 characters.

Reference is made to Item 2 of Part I of this quarterly report. “Management Discussion and Analysis or Plan of Operation-Forward Looking Statements”.

## Controls and procedures

As filed, 1,259 characters.

The Company’s management, including the Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of March 31, 2009 are effective to ensure that information required to be disclosed in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding disclosure.

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation that occurred during the Company’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

## Risk factors

As filed, 2,709 characters.

The following factors may affect the growth and profitability of Milestone and should be considered by any prospective purchaser or current holder of Milestone’s securities:

**We have no history of profitable operations. Continuing losses could exhaust our capital resources and force us to discontinue operations.**

For the three months ended March 31, 2009 and 2008 our revenues were approximately $2.2 million and $1.4 million respectively. In addition, we have had losses for each year since the commencement of operations, including net losses of approximately $562,000 and $616,000 for 2009 and 2008, respectively. At March 31, 2009, we had an accumulated deficit of approximately $57.8 million. At March 31, 2009, the Company had cash and cash equivalents $500,668 and working capital of $1,190,957. Additionally, the Company secured a line of credit in the aggregate amount $1.0 million from a stockholder which line was fully borrowed at December 31, 2007, as discussed in Note 5. This borrowing was amended to $1,300,000 as of September 30, 2008 under the same terms and conditions as the original. All borrowings and interest thereon must be repaid by June 30, 2010. Additionally, the Company borrowed $450,000 in 2008 from the same shareholder, with a due date of January 2009. This additional borrowing was refinanced at December 31, 2008 and the due date was extended to June 30, 2012. The Company, at March 31, 2009, expects to have sufficient cash reserves to meet all of its anticipated obligations through December 31, 2009. Additionally, the Company is actively pursuing the generation of positive cash flows from operating activities through increases in revenues based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses. If the Company is unable to generate positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that the Company will be able to achieve positive operating cash flows or that additional capital can be raised on the terms and conditions satisfactory to the Company if at all. If additional capital is required and it cannot be raised, then the Company would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost savings measures, any of which might negatively affect the Company’s operating results.

The Company’s recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern.

There are no other changes to our risk factors from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2008.

Filed May 7, 2009.
Source: SEC EDGAR, the filing index for accession 0001362310-09-006759. Last ingested by Listed: Nov 14, 2026, 11:14 ET. No prices; not investment advice.
